Transcat identified NEXA | EAM as a natural strategic fit to their growth strategy, which led to their acquisition in August 2021. The synergies between our two companies create a unique value proposition for our life sciences customers globally by offering our combined expertise and expanded suite of services. Together, the Transcat and NEXA teams will deliver even more efficient and effective asset management and calibration solutions to this highly regulated industry, where the cost of failure is very high. This will ensure our customers can safely deliver their life-saving, life-enhancing products to the market.